GlassScriptPhysician profile
Ian Z Qureshi
NPI 1871934547
$18,393.83
in general payments reported to CMS, 2019-2025
55 companies · $671 in 2025
The $671 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $415 · 2021: $782 · 2022: $2,885 · 2023: $5,719 · 2024: $6,793 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,653 · Food and Beverage: $3,019 · Education: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,652.50 |
| Food and Beverage | $3,018.98 |
| Education | $512.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,974.34 | 2019-2025 | Enhertu, Imjudo, Lynparza |
| Servier Pharmaceuticals LLC | $1,760.00 | 2022 | |
| Array Biopharma INC | $658.25 | 2022-2025 | Mektovi, Xalkori, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $472.13 | 2021-2025 | Opdivo, Opdualag |
| Seagen INC. | $461.90 | 2019-2023 | Adcetris |
| Pfizer INC. | $454.74 | 2019-2024 | |
| Janssen Biotech, INC. | $429.31 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Celgene Corporation | $410.81 | 2019-2025 | Reblozyl, Pomalyst |
| Incyte Corporation | $343.43 | 2019-2025 | Jakafi |
| Amgen INC. | $263.89 | 2019-2021 | |
| Lilly USA, LLC | $227.19 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $216.72 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Novocure Gmbh | $200.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $194.16 | 2022-2024 | Tecvayli, Darzalex, Rybrevant |
| Abbvie INC. | $179.30 | 2023-2025 |
Show all 53 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.